BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.